Keyword: Flemming Ornskov
Flemming Ornskov, Shire’s most recent CEO and who orchestrated the Baxalta takeover and later the selloff to Takeda, is now Galderma's CEO.
Ahead of what’s sure to be a big week for struggling Shire, a prominent investor group is rehashing complaints over the company’s executive pay policy.
Shire, Microsoft and patient group alliance Eurordis forged a partnership to accelerate diagnosis and treatment for rare diseases.
Shire has a penchant for making headlines at the J.P. Morgan Healthcare Conference, and it did so again early Monday.
Roche’s Genentech is out with a new threat to Shire’s hemophilia franchise—but the Dublin drugmaker’s CEO isn’t too concerned.
Shire CEO Flemming Ornskov acknowledged he could have done more to help investors understand the transition the company is making.
In one CEO popularity contest, biopharma chiefs are pretty average. But some top execs, including CEOs at Roche, AbbVie and Merck & Co., won kudos.
Rare disease drugmakers get that their typically high prices are under the lens these days—just like everyone else’s. But they don’t all necessarily agree that the scrutiny is fair.
The J.P. Morgan Healthcare Conference is starting to wind down in San Francisco, but that doesn't mean the news has diminished.
Deal talk is pretty hard to ignore at the J.P. Morgan Healthcare Conference—especially for a pair of the world’s biggest hemophilia drugmakers.